|Outcomes at 2–24 weeks (number of studies)||Weighted mean difference (95% CI)|
|Morning peak expiratory flow (l/min) (n=8)||33 (25 to 41)|
|Evening peak expiratory flow (l/min) (n=8)||26 (18 to 33)|
|Forced expiratory volume in 1 second (l) (n=8)||0.23 (0.14 to 0.31)|
|Daytime asthma symptom score (n=3)||−0.15 (−0.23 to −0.06)|
|Night time asthma symptom score (n=3)||−0.21 (−0.31 to −0.10)|
|Percentage of days without symptoms (n=2)||10 (2 to 19)|
|Percentage of nights without symptoms (n=3)||12 (8 to 16)|
|Daytime use of rescue bronchodilators (puffs/24 h) (n=4)||−0.33 (−0.50 to −0.16)|
|Night time use of rescue bronchodilators (puffs/24 h) (n=4)||−0.31 (−0.43 to −0.19)|
Review: regular inhaled long acting β2 agonists are associated with better outcomes than short acting β2 agonists in adults and children with chronic asthma
EBN Twitter Journal Club
The club runs like other journal discussion groups, except that the article and questions are posted on this blog and
the discussion about the article happens on Twitter.
How to participate >>
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.